Migraine headache is a debilitating disorder that affects millions of people in the United States and worldwide. The diagnosis of migraine can significantly affect quality of life, health care costs, and daily productivity. Hundreds of trials and many guidelines have documented various approaches to migraine management, whether via acute treatment or chronic migraine prophylaxis. Acute or abortive migraine management encompasses specific and nonspecific migraine therapeutics, including nonopioid and opioid analgesics, triptans, and ergotamines. Prophylactic migraine management data span the pharmacological spectrum from antiepileptic and antihypertensive agents to botulinum toxin type A. Special considerations for migraine management also must be applied in various populations, including children, pregnant women, and the elderly. The following review serves as an introduction to current therapeutic approaches for acute migraine treatment and provides an overview of available literature for pharmacological prophylaxis.
National Headache Foundation.NHF headache facts. www.headaches.org/factsheet.html. Accessed February 2008.
2.
Aukerman G., Knutsen D., Miser WFManagement of the acute migraine headache. Am Fam Physician . 2002;66:2123-2130.
3.
Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BMEvidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. U.S. Headache Consortium . www.aan.com/professionals/practice/pdfs/g10090.pdf . Accessed February 2008.
4.
Headache Classification Subcommittee of the International Headache Society.The international classification of headache disorders2nd ed. Cephalalgia . 2004;24:S1-S160.
Stewart WF, Lipton RB, Celentano DD, Reed MLPrevalence of migraine in the United States. JAMA. 1992;267:64-69.
7.
Snow V., Weiss K., Wall EM, Mottur-Pilson C.Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med.2002 ;840-849.
8.
Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. U.S.HeadacheConsortium.www.aan.com/public/practiceguidelines/03.pdf . Accessed February 2008.
9.
Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JPStratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA . 2000;284:2599-2605.
10.
Diamond M., Cady R.Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med.2005;118;18S-27S.
11.
Linde M.Migraine: a review and future directions for treatment. Acta Neurol Scand. 2006;114:71-83.
12.
Moore KL, Noble SLDrug treatment of migraine: Part I. Acute therapy and drug-rebound headache . Am Fam Physician. 1997;56:2039-2048.
13.
Jackson CMEffective headache management. Postgrad Med. 1998;104:133-147.
14.
Goldstein J. , Gawel MJ, Winner P., et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine . Headache . 1998;38:516-522.
15.
Loo CY, Tan HJ, Teh HS, Raymond AARandomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J. 2007;48:834-839.
16.
Maizels M.Intranasal lidocaine for migraine in an outpatient population. Headache. 1998;38:391.
17.
Maizels M., Scott B., Cohen W., Chen W.Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA. 1996;276:319-321.
18.
Saadah HAAbortive migraine therapy in the office with dexamethasone and prochlorperazine . Headache. 1994;34:366-370.
19.
Evers S., Afra J., Frese A., et al. EFNS guidelines on the drug treatment of migraine: a report of an EFNS task force. Eur J Neurol. 2006;13:560-572.
20.
Martin VY, Goldstein JAEvaluating the safety and tolerability profile of acute treatments for migraine . Am J Med. 2005;118:S36-S44.
Silberstein SD , McCrory DCErgotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 ;43:144-166.
23.
Modi S., Lowder DMMedications for migraine prophylaxis. Am Fam Physician . 2006;73:72-78.
24.
Linde K., Rossnagel K.Propranolol for migraine prophylaxis. Cochrane Database Syst Rev.2004;(2):CD003225.
25.
Tfelt-Hansen P., Standnes B., Kangasneimi P., Hakkarainen H., Olesen J.Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial . Acta Neurol Scand. 1984;69:1-8.
26.
Schellenberg R., Lichtenthal A., Wöhling H., Graf C., Brixius K.Nevibolol and metoprolol for treating migraine: an advance on β-blocker treatment? Headache. 2008;48:118-125.
27.
Olsson JE, Behring HC, Forssman B., et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. Acta Neurol Scand. 1984 ;70:160-168.
28.
Andersson PG , Dahl S., Hansen JH, et al. Prophylactic treatment of classical and non-classical migraine with metoprolol: a comparison with placebo. Cephalalgia. 1983;3:207-212.
29.
Kangasniemi P., Andersen PR, Andersson PG, et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia. 1987;7:231-238.
30.
Ryan REComparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J. 1984;108: 1156-1159.
31.
Peck RW, Seaber EJ, Dixon R., et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol. 1997;44:595-599.
32.
Solomon S.Major therapeutic advances in the past 25 years. Headache . 2007;47: S20-S22.
33.
Silberstein SD, Neto W., Schmitt J., Jacobs D.Topiramate in migraine prevention. Arch Neurol. 2004;61:490-495.
34.
Brandes JL, Saper JR, Diamond M., et al. Topiramate for migraine prevention. JAMA. 2004;291:965-973.
35.
Gupta P., Singh S., Goyal V., Shukla G., Behari M.Low-dose topiramate versus lamotrigine in migraine prophylaxis (the lotolamp study). Headache. 2007;47:401-412.
36.
Welch KM, D'Andrea G., Tepley N., Barkley G., Ramadan NMThe concept of migraine as a state of central neuronal hyperexcitability . Neurol Clin. 1990;8:817-828.
37.
Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652-1659.
38.
Silberstein SD, Collins SDSafety of divalproex sodium in migraine prophylaxis: an open-label long-term study. Headache . 1999 ;39:633-643.
39.
Shaygannejad V., Janghorbani M., Ghorbani A., Ashtary F., Zakisade N., Nasr V.Comparison of the effect of topiramate versus sodium valproate in migraine prevention: a randomized blinded crossover study . Headache. 2006;46:642-648.
40.
Ashkenazi A. , Benlifer A., Korenblit J., Silberstein SDZonisamide for migraine prophylaxis in refractory patients. Cephalalgia . 2006;26:1199-1202.
41.
Brighina F. , Palermo A., Aloisio A., Francolini M., Giglia G., Fierro B.Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol . 2006;29:338-342.
42.
Di Trapani G., Mei D., Marra C., Mazza S., Capuano A.Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter . 2000;151:145-148.
Couch JR, Ziegler DK, Hassanein R.Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology. 1976;26:121-127.
45.
Ziegler DK, Hurwitz A., Hassanein RS, Kodanaz HA, Preskorn SH, Mason J.Migraine prophylaxis: a comparison of propranolol and amitriptyline . Arch Neurol. 1987;44:486-489.
46.
Wong SL, Cavanaugh J., Shi H., Awni WM, Granneman GREffects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics . Clin Pharmacol Ther. 1996;60:48-53.
47.
Colucci d'Amato C., Pizza V., Marmolo T., Giordano E., Alfano V., Nasta A.Fluoxetine for migraine prophylaxis: a double-blind trial. Headache. 1999;39:716-719.
48.
Ozyalcin SN , Talu GK, Kiziltan E., Yucel B., Ertas M., Disci R.The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache . 2005 ;45:144-152.
49.
Bulut S., Berilgen MS, Baran A., Tekatas A., Atmaca M., Mungen B.Venlafaxine versus amitriptyline in prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg . 2004;107:44-48.
50.
Taylor AP, Adelman JU, Freeman MCEfficacy of duloxetine as a migraine preventative medication: possible predictors of response in a retrospective chart review. Headache . 2007;47:1200-1203.
51.
Charles JA, Jotkowitz S., Byrd LHPrevention of migraine with olmesartan in patients with hypertension/prehypertension . Headache. 2006;46:503-507.
Aurora SK, Gawel M., Brandes JL, Pokta S., VanDenburgh AMBotulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache . 2007;47:486-499.
56.
Silberstein S., Mathew N., Saper J., Jenkins S.Botulinum toxin type A as a migraine preventative treatment. Headache. 2000;40:445-450.
57.
Hershey AD, Winner PKPediatric migraine: recognition and treatment. J Am Osteopath Assoc. 2005;105:S2-S8.
58.
Reiter PD, Nickisch J., Merritt G.Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005;45:899-903.
59.
Taylor LM, Farzam F., Cook AM, Lewis DA, Baumann RJ, Kuhn RJClinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. Pharmacotherapy. 2007;27:519-525.
60.
Winner P., Gendolla A., Stayer C., et al. Topiramate for migraine prevention in adolescents: a pooled analysis of safety and efficacy. Headache. 2006;46: 1503-1510.
61.
Winner P., Pearlman E., Linder S., Jordan D., Fisher A., Hulihan J.Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:1304-1312.
62.
Eiland LSAnticonvulsant use for prophylaxis of the pediatric migraine. J Pediatr Health Care. 2007;21:392-395.
63.
Newman LCUnderstanding the causes and prevention of menstrual migraine: the role of estrogen. Headache. 2007;47: S86-S94.
64.
Graves BWManagement of migraine headaches. J Midwifery Womens Health . 2006;51:174-184.
65.
Silberstein SD, Lipton RB, Goadsby PJHeadache in Clinical Practice. London: Martin Dunitz; 2002.
66.
Fox AW, Diamond ML, Spierings ELH.Migraine during pregnancy: options for therapy. CNS Drugs . 2005;19:465-481.
67.
Aubé M.Migraine in pregnancy. Neurology . 1999;53:S26-S28.
68.
Sierpina V. , Astin J., Giordano J.Mind-body therapies for headache. Am Fam Physician. 2007;76:1518-1522.
69.
Campbell JK, Penzien DB, Wall EMEvidence-based guidelines for migraine headache: behavioral and physical treatments . April 25, 2000. http://www.aan.com/professionals/practice/pdfs/g10089.pdf. Accessed February 2008.
70.
Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Lexi-Comp's Drug Information Handbook. 13th ed. Hudson, OH : Lexi-Comp; 2005.
